ECSP19078239A - Péptido activador de receptor de gip - Google Patents

Péptido activador de receptor de gip

Info

Publication number
ECSP19078239A
ECSP19078239A ECSENADI201978239A ECDI201978239A ECSP19078239A EC SP19078239 A ECSP19078239 A EC SP19078239A EC SENADI201978239 A ECSENADI201978239 A EC SENADI201978239A EC DI201978239 A ECDI201978239 A EC DI201978239A EC SP19078239 A ECSP19078239 A EC SP19078239A
Authority
EC
Ecuador
Prior art keywords
activating peptide
gip
receiver activating
gip receiver
peptide
Prior art date
Application number
ECSENADI201978239A
Other languages
English (en)
Inventor
Mari Adachi
Naoki Nishizawa
Ayumu Niida
Tomoko Morimoto
Yoko Kanematsu
Shiro Takekawa
Taiji Asami
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of ECSP19078239A publication Critical patent/ECSP19078239A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un compuesto peptídico novedoso que tiene una acción activadora en los receptores de GIP y el uso del compuesto peptídico como un medicamento. Específicamente, se proporcionan un péptido que contiene una secuencia representada por la fórmula (I) o una sal de este y un medicamento que lo comprende. P1-Tyr-A2-Glu-Gly-Thr-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-P2 (I) en donde cada símbolo es como se definió en la presente.
ECSENADI201978239A 2017-03-31 2019-10-30 Péptido activador de receptor de gip ECSP19078239A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017072556 2017-03-31

Publications (1)

Publication Number Publication Date
ECSP19078239A true ECSP19078239A (es) 2019-12-27

Family

ID=62089992

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201978239A ECSP19078239A (es) 2017-03-31 2019-10-30 Péptido activador de receptor de gip

Country Status (22)

Country Link
US (2) US10435445B2 (es)
EP (1) EP3601329B1 (es)
JP (2) JP7175912B2 (es)
KR (1) KR102778100B1 (es)
CN (1) CN110709414B (es)
AR (1) AR111346A1 (es)
AU (2) AU2018246553B2 (es)
BR (1) BR112019020438A2 (es)
CA (1) CA3058361A1 (es)
CL (1) CL2019002790A1 (es)
CO (1) CO2019012271A2 (es)
EA (1) EA201992327A1 (es)
EC (1) ECSP19078239A (es)
IL (1) IL269581B2 (es)
JO (2) JOP20190211A1 (es)
MA (1) MA48998A (es)
MY (1) MY205279A (es)
PE (1) PE20200675A1 (es)
PH (1) PH12019502252A1 (es)
SG (1) SG11201908542QA (es)
TW (1) TWI801373B (es)
WO (1) WO2018181864A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3856339A1 (en) * 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
US12122815B2 (en) * 2018-09-24 2024-10-22 Takeda Pharmaceutical Company Limited GIP receptor agonist peptide compounds and uses thereof
AR119471A1 (es) 2019-08-01 2021-12-22 Lilly Co Eli Compuestos agonistas de gipr
EP4110800A1 (en) * 2020-03-06 2023-01-04 Sanofi Peptides as selective gip receptor agonists
CN115916812A (zh) * 2020-03-25 2023-04-04 武田药品工业株式会社 Gip受体激动剂肽化合物及其用途
CN115335395A (zh) * 2020-03-25 2022-11-11 武田药品工业株式会社 Gip受体激动剂肽化合物的qd给药及其用途
WO2021198229A1 (en) 2020-03-31 2021-10-07 Antaros Medical Ab Selective gip receptor agonists comprising a chelating moiety for imaging and therapy purposes
EP4185607A1 (en) 2020-07-22 2023-05-31 Novo Nordisk A/S Co-agonists at glp-1 and gip receptors suitable for oral delivery
IL306122B2 (en) * 2021-05-28 2026-01-01 Guangdong Raynovent Biotech Co Ltd Preparation and use of polypeptide
KR20240055069A (ko) 2021-09-06 2024-04-26 사노피 효력있는 선택적 gip 수용체 작용제로서의 신규 펩티드
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023084118A1 (en) 2021-11-15 2023-05-19 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
CN116891522B (zh) * 2022-04-01 2024-05-14 南京知和医药科技有限公司 一种长效胰高血糖素样肽-1衍生物及其制备方法和用途
US20260055142A1 (en) * 2022-04-07 2026-02-26 Guangdong Raynovent Biotech Co., Ltd. Pharmaceutical use of polypeptide in preparation of drugs for treating and/or preventing diabetes and obesity and related diseases thereof
EP4299052A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and a permeation enhancer
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
WO2024098718A1 (zh) * 2022-11-07 2024-05-16 内蒙古博睿精创科技有限公司 一种新型长效多肽化合物、组合物及其应用
EP4687947A1 (en) 2023-04-05 2026-02-11 Antag Therapeutics ApS Gip activity modulators and orthostatic intolerance
TW202529796A (zh) * 2023-11-22 2025-08-01 大陸商杭州中美華東製藥有限公司 Glp-1r/gipr雙標靶激動劑在製備動物藥的用途
WO2025154021A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025154020A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04145099A (ja) 1990-10-05 1992-05-19 Sanwa Kagaku Kenkyusho Co Ltd Ｇｉｐ様活性を有するポリペプチド誘導体及びその用途
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
GB0404124D0 (en) 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
BR0010750A (pt) 1999-05-17 2002-02-26 Conjuchem Inc Peptìdeos insulinotrópicos de longa duração
CA2416384A1 (en) 2000-07-17 2003-01-16 Takeda Chemical Industries, Ltd. Sulfone derivatives, their production and use
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
AU2003278600A1 (en) 2002-11-01 2004-05-25 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
CA2505322A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
EP1695961A4 (en) 2003-12-17 2007-10-24 Takeda Pharmaceutical UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
AU2004309271A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
JP4875978B2 (ja) 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
US7517910B2 (en) 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
KR20070115947A (ko) 2005-02-11 2007-12-06 아밀린 파마슈티칼스, 인크. 선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
WO2006121904A1 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
US20090054435A1 (en) 2005-07-29 2009-02-26 Hiroshi Imoto Phenoxyalkanoic Acid Compound
TW200740435A (en) 2005-08-10 2007-11-01 Takeda Pharmaceuticals Co Therapeutic agent for diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CA2623412A1 (en) 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
CA2622069A1 (en) 2005-09-08 2007-03-15 Uutech Limited Treatment of diabetes related obesity
WO2007109354A2 (en) 2006-03-21 2007-09-27 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
RS53230B (sr) 2006-06-27 2014-08-29 Takeda Pharmaceutical Company Limited Kondenzovana ciklična jedinjenja kao modulatori gpr40 receptora
WO2008021560A2 (en) 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable properties
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
US8492405B2 (en) 2006-10-18 2013-07-23 Takeda Pharmaceutical Company Limited Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity
RU2454415C9 (ru) 2006-10-19 2013-02-27 Такеда Фармасьютикал Компани Лимитед Производное индола
EP2128138A1 (en) 2007-01-29 2009-12-02 Takeda Pharmaceutical Company Limited Pyrazole compound
JP2010517935A (ja) 2007-02-09 2010-05-27 武田薬品工業株式会社 Ｐｐａｒ−ガンマのパーシャルアゴニストとしての縮合環化合物
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素５員複素環化合物
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
US8598314B2 (en) 2007-09-27 2013-12-03 Amylin Pharmaceuticals, Llc Peptide-peptidase-inhibitor conjugates and methods of making and using same
CN102105159B (zh) 2008-06-17 2015-07-08 印第安纳大学研究及科技有限公司 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
KR20110043687A (ko) 2008-08-07 2011-04-27 입센 파마 에스.에이.에스 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드의 절단형 유사체
ES2574835T3 (es) 2008-08-07 2016-06-22 Ipsen Pharma S.A.S. Análogos del polipéptido insulinotrópico dependiente de glucosa
WO2010016940A2 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
AU2009280021B2 (en) 2008-08-07 2012-10-04 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal
PE20120332A1 (es) 2008-12-19 2012-04-14 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida
EP2443146B1 (en) 2009-06-16 2016-10-05 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
WO2011014680A2 (en) 2009-07-31 2011-02-03 The Board Of Trustees Of The Leland Stanford Junior University Gastric inhibitory peptide variants and their uses
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
WO2012088379A2 (en) 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
US9453062B2 (en) 2011-06-10 2016-09-27 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
US20130090285A1 (en) 2011-06-27 2013-04-11 Phasebio Pharmaceuticals, Inc. Methods of treatment with glp-1 receptor agonists
IN2014MN02304A (es) 2012-05-03 2015-08-07 Zealand Pharma As
CN104583232B (zh) 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 展现gip受体活性的胰高血糖素类似物
PE20150863A1 (es) 2012-06-21 2015-06-11 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben actividad de receptor de gip
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
SI3004155T1 (sl) * 2013-05-28 2022-02-28 Takeda Pharmaceutical Company Limited Peptidna spojina
US20160185837A1 (en) 2013-08-16 2016-06-30 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
WO2015067715A2 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
CN105829339B (zh) 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
GB2528436A (en) 2014-07-15 2016-01-27 Lancaster Univ Business Entpr Ltd Treatment of neurological diseases
ES2685987T3 (es) 2014-09-05 2018-10-15 University Of Copenhagen Análogos de péptidos gip
KR102620911B1 (ko) 2014-10-29 2024-01-05 질랜드 파마 에이/에스 Gip 효능제 화합물 및 방법
WO2016077220A1 (en) 2014-11-10 2016-05-19 Mb2 Llc Gip/glp-1 co-agonist peptides for human administration
JP2018012644A (ja) 2014-11-26 2018-01-25 武田薬品工業株式会社 ペプチド化合物
TWI582109B (zh) 2015-01-09 2017-05-11 美國禮來大藥廠 Ｇｉｐ及ｇｌｐ－１共促效劑化合物
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
JP6326394B2 (ja) 2015-10-09 2018-05-16 Ｋｙｂ株式会社 ミキサ車の積載量計量装置
EP3368556B1 (en) 2015-10-28 2024-04-10 Tufts University Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
SG11201805586SA (en) 2015-12-31 2018-07-30 Hanmi Pharmaceutical Co Ltd Triple glucagon/glp-1/gip receptor agonist
JP6995042B2 (ja) 2016-05-24 2022-02-04 武田薬品工業株式会社 ペプチド化合物

Also Published As

Publication number Publication date
PH12019502252A1 (en) 2020-06-29
US20180298070A1 (en) 2018-10-18
BR112019020438A2 (pt) 2020-06-09
CO2019012271A2 (es) 2020-08-21
US11174301B2 (en) 2021-11-16
MY205279A (en) 2024-10-10
IL269581B2 (en) 2024-06-01
PE20200675A1 (es) 2020-06-11
JP7175912B2 (ja) 2022-11-21
AU2022200837A1 (en) 2022-03-03
EP3601329A1 (en) 2020-02-05
CN110709414A (zh) 2020-01-17
KR20190134626A (ko) 2019-12-04
AR111346A1 (es) 2019-07-03
CN110709414B (zh) 2025-02-11
SG11201908542QA (en) 2019-10-30
AU2018246553A1 (en) 2019-10-17
IL269581A (en) 2019-11-28
AU2018246553B2 (en) 2021-11-11
KR102778100B1 (ko) 2025-03-06
US20200140505A1 (en) 2020-05-07
JP2020515612A (ja) 2020-05-28
TWI801373B (zh) 2023-05-11
JOP20190211A1 (ar) 2019-09-15
WO2018181864A1 (en) 2018-10-04
EA201992327A1 (ru) 2020-02-19
TW201841936A (zh) 2018-12-01
IL269581B1 (en) 2024-02-01
JOP20180028A1 (ar) 2018-09-30
MA48998A (fr) 2020-02-05
CA3058361A1 (en) 2018-10-04
EP3601329B1 (en) 2024-12-04
JP2023012547A (ja) 2023-01-25
CL2019002790A1 (es) 2020-05-29
US10435445B2 (en) 2019-10-08

Similar Documents

Publication Publication Date Title
ECSP19078239A (es) Péptido activador de receptor de gip
ECSP15044389A (es) Compuesto peptídico
NI202000092A (es) Compuestos
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
AR094309A1 (es) Compuesto heterociclico fusionado y uso del mismo para el control de plagas
MX375170B (es) Compuestos de amida para el tratamiento de vih.
MX2016010559A (es) Compuesto heterociclico fusionado.
UY37367A (es) Nuevos compuestos para uso en el tratamiento de una infección viral y composiciones de los mismos
CR20160241A (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b
ECSP16067163A (es) Compuesto heterocíclico
CL2020000487A1 (es) Agentes antivirales contra la hepatitis b.
MX391414B (es) Compuesto novedoso de bifenilo o sal del mismo.
CO2020000134A2 (es) Compuestos cetónicos bicíclicos y métodos de uso de los mismos
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
ECSP16096831A (es) Derivados de naftiridinadiona
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
MX2021005234A (es) Compuestos para el tratamiento de la infeccion por arenavirus.
MX2016016061A (es) 2,2,2-trifluoroetil-tiadiazinas.
AR122557A2 (es) Oligonucleótido modificado
CR20150533A (es) Compuesto peptídico
TH165161A (th) สารประกอบเพพไทด์
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.
UA112287U (xx) Застосування вінборону для нівелювання антипроліферативного впливу ібупрофену на шлунковий епітелій